blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

Inclusive genomics: Unlocking equitable healthcare through diversity

Our new whitepaper "Inclusive genomics: A path to equitable precision medicine" offers a close look at the intersection of genomic research and diversity. It's an exploration of how embracing the full spectrum of human diversity is not just beneficial but essential for the advancement of precision medicine.

Continue reading

Reflections from the 34th International Symposium on ALS/MND

The 34th International Symposium on ALS/MND represented a pivotal moment in the ongoing fight against Amyotrophic Lateral Sclerosis (ALS). This year's event was especially significant, commemorating the 30th anniversary of the discovery of SOD1, the first monogenic cause of ALS, and showcasing the substantial progress made in understanding the genetic components of this complex disease.

Continue reading

Introducing "Light the Way:” A new dawn in ALS care and support

As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease also known as motor neuron disease (MND), is one such condition that has challenged medical experts for decades. Today, we’re thrilled to share a beacon of hope in this challenging landscape: Sano’s launch of “Light the Way.”

Continue reading

Introducing Light the Way [press release]

Families affected by ALS urged to join free program to uncover their genetic risk, contribute to research, and access new therapies

  • Sano Genetics launches ‘Light The Way’, offering peer support, DNA testing, genetic counseling and education to those diagnosed with or experiencing symptoms of ALS, and those at risk of genetic ALS due to their family history.
  • Around one in five ALS cases are now thought to be genetic; 40+ genes have been linked to the disease thanks to new discoveries funded in part by the 2014 ALS ice bucket challenge.*
  • Knowing their genetic risk could offer relief to many, while those who test positive may be able to access newly approved therapies, clinical trials and observational studies like Beacon, which charts the psychological impact of ALS genetic testing.

 

Continue reading

Engaging patients in precision medicine: Best practices for researchers

In the ever-evolving landscape of healthcare, precision medicine trials stand out as a beacon of personalised treatment, tailored to the unique genetic and environmental makeup of each individual. But the backbone of these trials isn't just cutting-edge technology or groundbreaking research; it's the patients. Engaging them effectively is both an art and a science. Here, we explore best practices for patient engagement in this dynamic field.

Continue reading

What are the economic implications of precision medicine?

As the interest in precision medicine grows, so does the interest in its economic implications. Economic evaluations are used to determine the value of treatments, helping policymakers allocate resources wisely. However, these evaluations can be difficult for precision medicine. In this blog post, we delve into the economics of precision medicine, exploring its cost-effectiveness and the broader economic benefits of tailored treatments.

Continue reading

ALS: Insights and innovations in treatment and research [report]

In our latest report, we explore the complexities of Amyotrophic Lateral Sclerosis (ALS), offering a comprehensive overview of the disease. From genetic components to the latest FDA-approved treatments, we cover the entire spectrum of ALS research and care.

Continue reading

A new horizon in liver disease management [whitepaper]

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a complex liver disease characterized by fat accumulation, inflammation, and fibrosis. With its global prevalence rising alongside obesity and type 2 diabetes rates, the medical community is urgently seeking innovative prediction, diagnosis, and treatment strategies.

Continue reading

Webinar recap: Bridging genomics and precision medicine

This webinar, hosted by Sano CEO Dr. Patrick Short and featuring David Ochoa, Platform Coordinator at Open Targets, explores the significance of human genetics in pinpointing drug targets, the variety of data sets employed, target safety, and methods of intervention. It also touches on the changing nature of drug modalities and prospective avenues for future research.

Continue reading

The pivotal role of genetic counselling in biotech and pharma precision medicine

The relationship between DNA and health is being understood better every day. We now know that our genes affect our risk of disease, symptoms, and even how we react to medications. But with genetic testing becoming a more prominent part of healthcare, genetic counsellors play a vital role in supporting people through the process and helping them understand the results of testing and what it means for them as patients. In this blog, we'll discuss the importance of genetic counsellors and how they bridge the gap between scientific advancement and patient care.

Continue reading